525
Participants
Start Date
September 21, 2015
Primary Completion Date
June 7, 2016
Study Completion Date
November 29, 2016
Ad26.ZEBOV 5*10^10 viral particles (vp)
Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
Ad26.ZEBOV 2*10^10 (vp)
Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2\*10\^10 viral particles on Day 1
Ad26.ZEBOV 0.8*10^10 (vp)
Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8\*10\^10 viral particles on Day 1
MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]
MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57
MVA-BN-Filo 5*10^7 Inf. U.
MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5\*10\^7 Inf. U. once on Day 57
Placebo
One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
Huntsville
San Diego
Melbourne
Peoria
Mishawaka
Rockville
Janssen Vaccines & Prevention B.V.
INDUSTRY